Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a ...
The decision to clear another mifepristone generic sparked political backlash. Elsewhere, Medicare delayed a decision on whether to subject “combination” drugs to pricing negotiations, and a cancer ...
In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, ...
The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...
George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...
In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...
The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be ...
The company has received a “limited number” of non-binding proposals, mostly from groups of financial investors, for a ...
The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with ...
Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA ...
The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while ...
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results